KRX •
Healthcare •
Biotechnology •
Quote as of 06/12/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeKRX
Market Capitalization804,654 mln
Float39.84 mln
Earnings Date08/15/2025
EPS
725
Exceptional
P / E
20.35
Premium valuation
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.59
Likely reliable
1-Year Forecast
26,000
Transformational upside
Relative Strength
53
/ 100
Slightly ahead
Business Description
Pharmicell Co., Ltd. is a South Korea-based biopharmaceutical company founded in 1968 that specializes in developing and commercializing therapies derived from a patient's own stem cells. Its lead product, Cellgram-AMI, uses bone marrow-derived stem cells to support heart recovery following a heart attack, while additional treatments targeting liver disease and erectile dysfunction are currently in development. The company also produces chemical intermediates and cell culture media, and operates a stem cell banking service under the Twelve brand.
